{
    "eid": "2-s2.0-85073178758",
    "title": "Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial",
    "cover-date": "2019-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "bictegravir",
        "HIV",
        "INSTI",
        "tenofovir alafenamide",
        "women"
    ],
    "authors": [
        "Cissy Kityo",
        "Debbie Hagins",
        "Ellen Koenig",
        "Anchalee Avihingsanon",
        "Ploenchan Chetchotisakd",
        "Khuanchai Supparatpinyo",
        "Natalya Gankina",
        "Vadim Pokrovsky",
        "Evgeny Voronin",
        "Jeffrey L. Stephens",
        "Edwin Dejesus",
        "Hui Wang",
        "Rima K. Acosta",
        "Huyen Cao",
        "Erin Quirk",
        "Hal Martin",
        "Tariro Makadzange"
    ],
    "citedby-count": 26,
    "ref-count": 32,
    "ref-list": [
        "Women's involvement in clinical trials: Historical perspective and future implications",
        "A systematic review of the inclusion (or exclusion) of women in HIV research: From clinical studies of antiretrovirals and vaccines to cure strategies",
        "Does patient sex affect human immunodeficiency virus levels?",
        "Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients",
        "Gender differences in pharmacological response",
        "Sex differences in pharmacokinetics and pharmacodynamics",
        "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel",
        "Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults",
        "Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile",
        "Lack of pharmacokinetic and pharmacodynamic interactions between the integrase strand transfer inhibitor bictegravir and the oral contraceptive ethinyl estradiol/norgestimate",
        "Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial",
        "Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial",
        "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed HIV-1 infected adults: A randomised, double-blinded, multicentre, active-controlled, phase 3, non-inferiority trial",
        "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed HIV-1 infected adults: A randomised, open-label, multicentre, active-controlled, phase 3, non-inferiority trial",
        "Patient-reported symptoms over 48 Weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus Co-formulated abacavir, dolutegravir, and lamivudine",
        "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): A randomised, controlled, double-blind, phase 3 study",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials",
        "A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions",
        "Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): A 48-week, randomized, non-inferiority, open-label, Phase IIIb study",
        "Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients",
        "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France",
        "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: A randomised, double-blind, multicentre, phase 3b, non-inferiority study",
        "Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: A randomised, double-blind, multicentre, phase 3b, non-inferiority study",
        "Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-inferiority, phase 3b study",
        "Neural-tube defects with dolutegravir treatment from the time of conception"
    ],
    "affiliation": [
        {
            "affiliation-city": "Kampala",
            "@id": "60071691",
            "affilname": "Joint Clinical Research Center Uganda",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691",
            "affiliation-country": "Uganda"
        },
        {
            "affiliation-city": "Moscow",
            "@id": "60069625",
            "affilname": "Ministry of Health of Russian Federation",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069625",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Macon",
            "@id": "60026005",
            "affilname": "Mercer University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026005",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Krasnoyarsk",
            "@id": "115403233",
            "affilname": "Krasnoyarsk Regional Center for Prevention and Control of AIDS",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115403233",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Savannah",
            "@id": "113700425",
            "affilname": "Chatham Care Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Moscow",
            "@id": "108398532",
            "affilname": "Moscow Regional Center for the Prevention and Control of AIDS and Infectious Diseases",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108398532",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Santo Domingo",
            "@id": "105310604",
            "affilname": "Instituto Dominicano de Estudios Virologicos (IDEV)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/105310604",
            "affiliation-country": "Dominican Republic"
        },
        {
            "affiliation-city": "Orlando",
            "@id": "100429817",
            "affilname": "Orlando Immunology Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100429817",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Gilead"
    ]
}